Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults

被引:4
作者
Geng, Tingting [1 ,2 ]
Xu, Wenqi [3 ,4 ]
Gao, Huanqing [5 ]
Zhang, Jijuan [2 ]
Zou, Jiaojiao [1 ]
Wang, Kaiyue [1 ]
Li, Junjuan [3 ]
Guo, Lu [4 ]
Wang, Guodong [4 ]
Chen, Shuohua [4 ]
Huang, Tao [6 ]
Pan, An [2 ]
Gao, Xiang [1 ]
Wu, Shouling [3 ]
机构
[1] Fudan Univ, Inst Nutr, Sch Publ Hlth, Dept Nutr & Food Hyg,Zhongshan Hosp, Shanghai, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China
[3] Kailuan Gen Hosp, Dept Cardiol, 57 Xinhua East Rd, Tangshan 063000, Peoples R China
[4] North China Univ Sci & Technol, Grad Sch, Tangshan, Peoples R China
[5] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[6] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing, Peoples R China
关键词
blood glucose; cardiovascular disease; chronic kidney disease; low-density lipoprotein cholesterol; mortality; systolic blood pressure; MULTIFACTORIAL INTERVENTION; MANAGEMENT; CKD; ASSOCIATION; OUTCOMES; DAPAGLIFLOZIN; PROTEINURIA; GUIDELINES; HEART;
D O I
10.1016/j.jacc.2024.06.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Patients with chronic kidney disease (CKD) are at an elevated risk of cardiovascular disease (CVD) and premature mortality compared to the general population. OBJECTIVES This study aimed to investigate whether the excess risk of CVD events and death among patients with CKD could be reduced or eliminated through strict control of blood pressure (systolic blood pressure: <130 mm Hg), lipids (low-density lipoprotein cholesterol: <2.6 mmol/L), and glucose (fasting blood glucose: <6.1 mmol/L). METHODS The authors included 20,254 patients with CKD who were free of CVD or end-stage renal disease and matched them with 35,236 control individuals based on age (f2 years) and sex from the Kailuan study. RESULTS During a median follow-up period of 12.2 to 12.8 years, 3,875 deaths, 1,888 cases of stroke, 513 cases of myocardial infarction, and 4,825 cases of CKD progression were documented. Among patients with CKD, risk factor controls showed an association with a reduction in myocardial infarction, stroke, CKD progression, and all-cause mortality risk in a dose-dependent manner. Moreover, compared to the non-CKD control individuals, having all 3 risk factors within the target ranges could theoretically eliminate the excess risk of CVD and mortality associated with CKD. Among patients with CKD who had all 3 risk factors controlled, the HRs were 0.80 (95% CI: 0.56-1.14) for myocardial infarction, 0.93 (95% CI: 0.78-1.12) for stroke, and 1.10 (95% CI: 0.98-1.24) for all-cause mortality compared to the non-CKD control individuals. CONCLUSIONS Patients with CKD who had controlled blood pressure, lipids, and glucose showed no excess risk of death, myocardial infarction, or stroke compared to the general population. (JACC. 2024;84:1313-1324) (c) 2024 by the American College of Cardiology Foundation.
引用
收藏
页码:1313 / 1324
页数:12
相关论文
共 39 条
  • [1] Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease
    Agarwal, Rajiv
    Sinha, Arjun D.
    Cramer, Andrew E.
    Balmes-Fenwick, Mary
    Dickinson, Jazmyn H.
    Ouyang, Fangqian
    Tu, Wanzhu
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (27) : 2507 - 2519
  • [2] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Baigent, Colin
    Landray, Martin J.
    Reith, Christina
    Emberson, Jonathan
    Wheeler, David C.
    Tomson, Charles
    Wanner, Christoph
    Krane, Vera
    Cass, Alan
    Craig, Jonathan
    Neal, Bruce
    Jiang, Lixin
    Hooi, Lai Seong
    Levin, Adeera
    Agodoa, Lawrence
    Gaziano, Mike
    Kasiske, Bertram
    Walker, Robert
    Massy, Ziad A.
    Feldt-Rasmussen, Bo
    Krairittichai, Udom
    Ophascharoensuk, Vuddidhej
    Fellstrom, Bengt
    Holdaas, Hallvard
    Tesar, Vladimir
    Wiecek, Andrzej
    Grobbee, Diederick
    de Zeeuw, Dick
    Gronhagen-Riska, Carola
    Dasgupta, Tanaji
    Lewis, David
    Herrington, William
    Mafham, Marion
    Majoni, William
    Wallendszus, Karl
    Grimm, Richard
    Pedersen, Terje
    Tobert, Jonathan
    Armitage, Jane
    Baxter, Alex
    Bray, Christopher
    Chen, Yiping
    Chen, Zhengming
    Hill, Michael
    Knott, Carol
    Parish, Sarah
    Simpson, David
    Sleight, Peter
    Young, Alan
    Collins, Rory
    [J]. LANCET, 2011, 377 (9784) : 2181 - 2192
  • [3] Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
    Bikbov, Boris
    Purcell, Carrie
    Levey, Andrew S.
    Smith, Mari
    Abdoli, Amir
    Abebe, Molla
    Adebayo, Oladimeji M.
    Afarideh, Mohsen
    Agarwal, Sanjay Kumar
    Agudelo-Botero, Marcela
    Ahmadian, Elham
    Al-Aly, Ziyad
    Alipour, Vahid
    Almasi-Hashiani, Amir
    Al-Raddadi, Rajaa M.
    Alvis-Guzman, Nelson
    Amini, Saeed
    Andrei, Tudorel
    Andrei, Catalina Liliana
    Andualem, Zewudu
    Anjomshoa, Mina
    Arabloo, Jalal
    Ashagre, Alebachew Fasil
    Asmelash, Daniel
    Ataro, Zerihun
    Atout, Maha Moh'd Wahbi
    Ayanore, Martin Amogre
    Badawi, Alaa
    Bakhtiari, Ahad
    Ballew, Shoshana H.
    Balouchi, Abbas
    Banach, Maciej
    Barquera, Simon
    Basu, Sanjay
    Bayih, Mulat Tirfie
    Bedi, Neeraj
    Bello, Aminu K.
    Bensenor, Isabela M.
    Bijani, Ali
    Boloor, Archith
    Borzi, Antonio M.
    Camera, Luis Alberto
    Carrero, Juan J.
    Carvalho, Felix
    Castro, Franz
    Catala-Lopez, Ferran
    Chang, Alex R.
    Chin, Ken Lee
    Chung, Sheng-Chia
    Cirillo, Massimo
    [J]. LANCET, 2020, 395 (10225) : 709 - 733
  • [4] The Pros and Cons of Diagnosing Diabetes With A1C
    Bonora, Enzo
    Tuomilehto, Jaakko
    [J]. DIABETES CARE, 2011, 34 : S184 - S190
  • [5] 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
    Catapano, Alberico L.
    Graham, Ian
    De Backer, Guy
    Wiklund, Olov
    Chapman, M. John
    Drexel, Heinz
    Hoes, Arno W.
    Jennings, Catriona S.
    Landmesser, Ulf
    Pedersen, Terje R.
    Reiner, Zeljko
    Riccardi, Gabriele
    Taskinen, Marja-Riita
    Tokgozoglu, Lale
    Monique, W. M.
    Verschuren, W. M. Monique
    Vlachopoulos, Charalambos
    Wood, David A.
    Luis Zamorano, Jose
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (39) : 2999 - +
  • [6] Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
    Charytan, David M.
    Sabatine, Marc S.
    Pedersen, Terje R.
    Im, KyungAh
    Park, Jeong-Gun
    Pineda, Armando Lira
    Wasserman, Scott M.
    Deedwania, Prakash
    Olsson, Anders G.
    Sever, Peter S.
    Keech, Anthony C.
    Giugliano, Robert P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (23) : 2961 - 2970
  • [7] Cherney DZI, 2020, LANCET DIABETES ENDO, V8, P582, DOI 10.1016/S2213-8587(20)30162-5
  • [8] Effects of Intensive BP Control in CKD
    Cheung, Alfred K.
    Rahman, Mahboob
    Reboussin, David M.
    Craven, Timothy E.
    Greene, Tom
    Kimmel, Paul L.
    Cushman, William C.
    Hawfield, Amret T.
    Johnson, Karen C.
    Lewis, Cora E.
    Oparil, Suzanne
    Rocco, Michael V.
    Sink, Kaycee M.
    Whelton, Paul K.
    Wright, Jackson T., Jr.
    Basile, Jan
    Beddhu, Srinivasan
    Bhatt, Udayan
    Chang, Tara I.
    Chertow, Glenn M.
    Chonchol, Michel
    Freedman, Barry I.
    Haley, William
    Ix, Joachim H.
    Katz, Lois A.
    Killeen, Anthony A.
    Papademetriou, Vasilios
    Ricardo, Ana C.
    Servilla, Karen
    Wall, Barry
    Wolfgram, Dawn
    Yee, Jerry
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (09): : 2812 - 2823
  • [9] 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk
    Colantonio, Lisandro D.
    Booth, John N., III
    Bress, Adam P.
    Whelton, Paul K.
    Shimbo, Daichi
    Levitan, Emily B.
    Howard, George
    Safford, Monika M.
    Muntner, Paul
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (11) : 1187 - 1197
  • [10] Is the KDIGO Systolic Blood Pressure Target &lt;120 mm Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice?
    Dasgupta, Indranil
    Zoccali, Carmine
    [J]. HYPERTENSION, 2022, 79 (01) : 4 - 11